Antiepileptic Effect and Safety Profile of Rapamycin in Pediatric Patients With Tuberous Sclerosis Complex

202218 citationsJournal Articlegold Open Access

Authors

Krzysztof Sadowski · Children's Memorial Health Institute

Kamil Sijko · Transition Technologies (Poland)

Dorota Domańska‐Pakieła · Children's Memorial Health Institute

Julita Borkowska · Children's Memorial Health Institute

Dariusz Chmielewski · Children's Memorial Health Institute

Agata Ulatowska · Children's Memorial Health Institute

Sergiusz Jóźwiak

Abstract

Long-term use of rapamycin, especially in combination with vigabatrin, might be a beneficial therapeutic option in the treatment of drug-resistant epilepsy in children with TSC.

Topics & Keywords

Tuberous Sclerosis Complex Research Polyomavirus and related diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Frontiers in Neurology

Volume 13, pp. 704978-704978

DOI: 10.3389/fneur.2022.704978

Field-Weighted Citation Impact: 2.01